KPV

KPV is a naturally occurring tripeptide consisting of lysine-proline-valine, derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). Despite being only three amino acids in length, KPV retains significant inflammatory-marker modulation activity in preclinical studies attributable to the parent hormone. Research has demonstrated that KPV exerts its effects primarily through inhibition of the NF-κB signaling pathway, a master regulator of inflammatory gene expression. This mechanism has been documented in multiple cell types including colonocytes, keratinocytes, and immune cells.

Preclinical studies have highlighted KPV's activity in gastrointestinal inflammation research models. Studies using murine colitis research models have shown that KPV can modulate inflammatory markers and attenuate tissue-damage readouts when administered orally or via nanoparticle delivery systems. The peptide has been shown to inhibit the activation of NF-κB by preventing the phosphorylation and degradation of IκBα, thereby reducing the transcription of pro-inflammatory cytokine markers including TNF-α, IL-1β, and IL-6.

Beyond gastrointestinal preclinical models, KPV has been investigated for its immunomodulatory properties in dermatological research models. Its parent peptide α-MSH is known to signal through melanocortin receptors, and KPV appears to retain some capacity to interact with these receptor pathways, contributing to its broad inflammatory-marker modulation profile across multiple tissue research models.